Table of Contents Author Guidelines Submit a Manuscript
Volume 2009, Article ID 605840, 6 pages
Clinical Study

The Value of Surgery for Retroperitoneal Sarcoma

1Stanford University School of Medicine, Stanford, CA 94305, USA
2Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
3Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
4Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA
5Department of Surgery, Stanford University, Stanford, CA 94305, USA

Received 7 November 2008; Revised 8 May 2009; Accepted 15 July 2009

Academic Editor: Alessandro Gronchi

Copyright © 2009 Sepideh Gholami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction. Retroperitoneal sarcomas are uncommon large malignant tumors. Methods. Forty-one consecutive patients with localized retroperitoneal sarcoma were retrospectively studied. Results. Median age was 58 years (range 20–91 years). Median tumor size was 17.5 cm (range 4–41 cm). Only 2 tumors were <5 cm. Most were liposarcoma (44%) and high-grade (59%). 59% were stage 3 and the rest was stage 1. Median followup was 10 months (range 1–106 months). Thirty-eight patients had an initial complete resection; 15 (37%) developed recurrent sarcoma and 12 (80%) had a second complete resection. Patients with an initial complete resection had a 5-year survival of 46%. For all patients, tumor grade affected overall survival ( 𝑃 = . 0 0 6 ). Complete surgical resection improved overall survival for high-grade tumors ( 𝑃 = . 0 3 ). Conclusions. Tumor grade/stage and complete surgical resection for high-grade tumors are important prognostic variables. Radiation therapy or chemotherapy had no significant impact on overall or recurrence-free survival. Complete surgical resection is the treatment of choice for patients with initial and locally recurrent retroperitoneal sarcoma.